Company profile

Asher Biotherapeutics, Inc.

Privately held: no public share price (Privately held, VC-backed; closed a $55M Series C in April 2024, no ticker. [resolved 2026-08-05 by resolve-null-is-public; source: https://asherbio.com/2024/04/16/asher-bio-closes-55-million-series-c-financing-to-advance-lead-program-into-phase-1b-clinical-trials/]) · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
AB248
Phase 1
CD8 (delivery anchor) / IL-2 receptorProtein / enzyme therapeutic
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.